abiraterone acetate,darolutamide,docetaxel
bayer
['triplet']
not completely true! docetaxel was not planned and the numbers of patients receiving it are &lt; 50% of the trial. in some exploratory analysis and toghether with peace-1 and arasens i think that triplet has a role in high risk, symptomatic and/or high tumor burden patients #asco22 
Scientific Committee Member LACOG - GU. Medical Oncologist at Hospital Albert Einstein and CPO. Owner and founder BIO. Following or RT does not mean endorsement